Cocrystal Pharma, Inc. financial data

Symbol
COCP on Nasdaq
Location
19805 N. Creek Parkway, Bothell, WA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 509 % -50.7%
Debt-to-equity 40.1 % +161%
Return On Equity -144 % -95%
Return On Assets -103 % -60.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.3M shares +0.84%
Common Stock, Shares, Outstanding 10.2M shares 0%
Entity Public Float 18M USD -2.7%
Common Stock, Value, Issued 10K USD 0%
Weighted Average Number of Shares Outstanding, Basic 10.2M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 10.2M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.76M USD -50.6%
General and Administrative Expense 4.96M USD -11.4%
Operating Income (Loss) -12.7M USD +32%
Nonoperating Income (Expense) 160K USD -79.7%
Net Income (Loss) Attributable to Parent -12.6M USD +29.9%
Earnings Per Share, Basic -1 USD/shares +29.3%
Earnings Per Share, Diluted -1 USD/shares +29.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.86M USD -62.6%
Assets, Current 6.77M USD -65.6%
Property, Plant and Equipment, Net 107K USD -49.3%
Operating Lease, Right-of-Use Asset 1.55M USD -7.65%
Assets 8.51M USD -60.6%
Accounts Payable, Current 856K USD -50.9%
Employee-related Liabilities, Current 106K USD -32.1%
Liabilities, Current 1.83M USD -31%
Operating Lease, Liability, Noncurrent 1.34M USD -12.3%
Liabilities 3.17M USD -24.2%
Retained Earnings (Accumulated Deficit) -338M USD -3.86%
Stockholders' Equity Attributable to Parent 5.33M USD -69.3%
Liabilities and Equity 8.51M USD -60.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.94M USD +34.7%
Net Cash Provided by (Used in) Financing Activities -7K USD -16.7%
Net Cash Provided by (Used in) Investing Activities -8K USD +82.2%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 10.2M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.94M USD +34.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.1M USD
Deferred Tax Assets, Valuation Allowance 35.2M USD +11.9%
Deferred Tax Assets, Gross 35.6M USD +11.5%
Operating Lease, Liability 1.66M USD -6.85%
Depreciation 45K USD
Payments to Acquire Property, Plant, and Equipment 8K USD -82.2%
Lessee, Operating Lease, Liability, to be Paid 1.93M USD -9.62%
Property, Plant and Equipment, Gross 2.08M USD 0%
Operating Lease, Liability, Current 317K USD +26.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 415K USD +16.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 419K USD +21.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 268K USD -23.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 376K USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 23.7M USD +7.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 249K USD -33.8%
Operating Lease, Payments 56K USD +12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 35.2M USD +11.9%
Share-based Payment Arrangement, Expense 486K USD -25.7%
Interest Expense -220K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%